SARS-CoV-2 nsp14-IN-2 

SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an IC₅₀ value of 0.093 µM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19^[1].

IC₅₀: 0.093 µM (SARS-CoV-2 Nsp14 methyltransferase)^[1].

SARS-CoV-2 nsp14-IN-2 (compound 10) (0-100 µM) shows antiviral activity with an EC₅₀ value of 0.72 µM and CC₅₀ value of >100 µM^[1].
SARS-CoV-2 nsp14-IN-2 (24 h) shows plasma stability with t_1/2s of >24, >24 h for human and mouse, respectively^[1].
SARS-CoV-2 nsp14-IN-2 (45 min) shows liver S9 stability with t_1/2 values of 842 min and >45 min in Phase I and phase II in human liver, respectively; and t_1/2 values of 28.9 min and >45 min in Phase I and phase II in mouse liver, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

455.49

C₂₁H₂₁N₅O₅S

2816165-16-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Eunkyung Jung， et al. Bisubstate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. ACS Med. Chem. Lett. 2022.